Bruker : Jefferies 2022 Global Healthcare Conference

BRUKER CORPORATION (NASDAQ: BRKR)

Bruker Corporation

Jefferies Healthcare Conference Presentation

June 9, 2022

Frank H. Laukien, President & CEO

Justin Ward, Senior Director, Investor Relations & Corporate Development

BRUKER CORPORATION

Safe Harbor Statement

Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our fiscal year 2022 financial outlook, our outlook for organic revenue growth, non-GAAP operating margin, non- GAAP EPS and non-GAAP tax rate; management's expectations for the impact of foreign currency and acquisitions, and for future financial and operational performance and business outlook; future economic conditions; the duration and impact of supply chain challenges; and strategic investments Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, risks and uncertainties relating to the length and severity of the COVID-19 pandemic, the impact of the pandemic on global economic conditions and the length and severity of any resulting recession, the impact of any supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any resulting sanctions, continued volatility in the capital markets, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, our restructuring and cost control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing, and outsourcing, competition, dependence on collaborative partners, key suppliers and third-party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, our ability to service our obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2021, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward- looking statements other than as required by law.

© 2022 Bruker	+	-Bruker	Innovation with Integrity |	June 9, 2022	|	2
		Confidential-

Q1 2022 BUSINESS UPDATE

Q1 2022: Continued Strong Organic Revenue Growth on Solid Demand for our Differentiated Products and Solutions

Q1 2022 Performance Year-over-Year

Q1 Financials

• Organic bookings growth for BSI strong with book-to-bill >1.1

Revenues [$M]

• Revenue increase of $40.3M, or +7.3%
• • Organic growth of +10.5%, with BSI up +9.5% and BEST up +21.0%, despite supply chain and logistics challenges
  • Acquisitions add +1.0%; FX headwind of -4.2%
• Non-GAAPgross margin of 52.7%, up +140 bps
• Non-GAAPoperating margin of 19.5%, up +110 bps
• GAAP EPS of $0.41, up 10.8%
• Non-GAAPEPS of $0.49, up 11.4%
• Non-GAAPROIC of 27.6% for trailing twelve months

Reconciliations of non-GAAP to GAAP financial measures are available in our earnings press release. Y-o-y: year over year. Bps: basis points

© 2022 Bruker	+	-Bruker
		Confidential-

595.0	+7.3%
554.7
Q1-22	Q1-21

Non-GAAP EPS

Q1-21						+11.4%
Q1-22

Innovation with Integrity |

June 9, 2022

|

3

FY 2022 GUIDANCE - RAISED ON MAY 4TH, 2022

FY 2022 Outlook

FY 2022 Guidance	Year-over-year
Revenue Growth	+5% to +7%
Non-GAAP Operating Margin	+30 bps to +60 bps
Expansion(1)
Non-GAAP EPS	$2.29 to $2.33,
	Up 9% to 11%

1. To 19.7% to 20.0% in FY 2022 from a FY 2021 non-GAAP operating margin of 19.4%.

© 2022 Bruker	+	-Bruker
		Confidential-

FY 2022 Assumptions

• Organic revenue growth +7 to +9%; raised +1% from prior guidance
• FX revenue headwind approx. -3.5%; vs. -2% prior
• Acquisitions revenue tailwind ~+1.5%; vs. +1% prior
• Non-GAAPtax rate: ~29.5%
• Fully diluted share count: ~151M
• CAPEX: ~$115M
• FX assumptions for remainder of year (rates as of

March 31, 2022):

EUR = 1.11 USD; CHF = 1.08 USD; Yen = 121.6 USD

Innovation with Integrity |

June 9, 2022

|

4

TRANSFORMATION UPDATE

Innovation and Multiyear Transformation Delivering Shareholder Value Accelerated Revenue Growth & Continuing Margin Expansion, With Top-TierROIC

Revenue Growth Acceleration	Significant non-GAAP Operating				Non-GAAP EPS DD CAGR
								Margin expansion, ROIC >20%
							$2.4B										28%										$2.10
																ROIC
						$2.1B	$2.0B	28% 27% 27%	27% 21%										$1.57
															$1.35
$	1.8B	$1.6B $1.6B$1.8B $1.9B		23%						19.4%	Non-GAAP								$1.40
					16.8%	17.6%	Operating Margin	$1.19	$1.21
								13.5% 15.0% 15.9%	16.0%
										$0.89
								10.2%										$0.75
								YoY Organic
			2%		(2%)	4% 4% 6%	(6)% 19%	GrowthRevenue
																			2014 2015 2016 2017 2018 2019 2020 2021
	2014 2015 2016 2017 2018 2019 2020 2021	2014 2015 2016 2017 2018 2019 2020 2021
							5.7%

2014-2016: RESTRUCTURING &	2017-2020: PROJECT ACCELERATE
TRANSFORMATION	& OPERATIONAL EXCELLENCE
▪ Cost out, consolidation and divestitures	▪	Portfolio transformation
▪ New organization & management process	▪	Entrepreneurial Bruker Management Process
▪ Integrated ERP, SF CRM adoption	▪	Improved productivity
▪	New HR compensation/incentives	▪	Shared services centers
▪	Increased outsourcing	▪ Enhanced compliance & risk management

2021-202X: PROJECT ACCELERATE 2.0

& OPERATIONAL EXCELLENCE GOALS

• Major opportunities in Proteomics, Metabolomics and Spatial Biology
• Microbiology & Molecular DX
• Biopharma & Applied, Semi Metrology
• Aftermarket, Consumables & Software
• Further improved productivity, tax rate

© 2022 Bruker	(1) Reconciliations of non-GAAP organic growth, non-GAAP operating margin and non-GAAP EPS to the most directly comparable GAAP measures are available at	Innovation with Integrity |	June 9, 2022	|	5
+	-Bruker

the end of this presentation.

Confidential-